What is Zacks Research's Estimate for Neogen Q1 Earnings?

Neogen Corporation (NASDAQ:NEOG - Free Report) - Stock analysts at Zacks Research dropped their Q1 2027 earnings per share estimates for Neogen in a research note issued on Wednesday, July 23rd. Zacks Research analyst R. Department now expects that the company will post earnings of $0.09 per share for the quarter, down from their prior estimate of $0.10. The consensus estimate for Neogen's current full-year earnings is $0.38 per share.

Several other research firms have also weighed in on NEOG. Guggenheim cut their target price on shares of Neogen from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, June 30th. Piper Sandler dropped their price objective on shares of Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a report on Tuesday, April 22nd.

Neogen Stock Up 3.8%

NASDAQ:NEOG traded up $0.20 during trading hours on Thursday, reaching $5.42. The company's stock had a trading volume of 5,180,200 shares, compared to its average volume of 5,276,995. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -2.43 and a beta of 1.77. Neogen has a one year low of $3.87 and a one year high of $18.58. The business's 50-day moving average is $5.38 and its 200-day moving average is $7.47. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.91 and a quick ratio of 2.45.

Insider Buying and Selling at Neogen

In related news, Director Aashima Gupta bought 16,000 shares of Neogen stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average price of $6.25 per share, with a total value of $100,000.00. Following the acquisition, the director owned 21,917 shares of the company's stock, valued at approximately $136,981.25. This represents a 270.41% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.13% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neogen

A number of institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc boosted its stake in shares of Neogen by 1,495.4% in the 1st quarter. Versant Capital Management Inc now owns 3,127 shares of the company's stock valued at $27,000 after purchasing an additional 2,931 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Neogen in the 4th quarter valued at $43,000. Covestor Ltd boosted its stake in shares of Neogen by 41.4% in the 4th quarter. Covestor Ltd now owns 4,103 shares of the company's stock valued at $50,000 after purchasing an additional 1,202 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Neogen by 388.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 10,071 shares of the company's stock valued at $87,000 after purchasing an additional 8,010 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in shares of Neogen by 4,955.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 10,415 shares of the company's stock valued at $126,000 after purchasing an additional 10,209 shares during the last quarter. 96.73% of the stock is currently owned by institutional investors and hedge funds.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.